Grant: Project Grant
University of Toronto
$753,524.00
Extending life in refractory medulloblastoma patients with cancer stem cell killing small molecules
FY 2016-17
Summary
We have discovered a small drug-like molecule that has demonstrated extremely potent killing of chemotherapy and radiation-resistant children's brain cancer cells. Children that develop this resistant form of brain cancer are palliative with no other available treatment options. This molecule, named JP-4-94, was discovered by rationale design, and found to exhibit exquisite potency against a protein, c-Myc, long known to be a major driver of many human cancers. Moreover, this molecule has been validated in mouse models as having incredible metabolic stability and can be found in high concentrations in the blood stream with no toxicity to the mouse. We propose to optimize this compound further toward a preclinical candidate and evaluate its efficacy in the most aggressive of Children's brain cancer. We expect by grant end, that we will have identified an advanced preclinical candidate.
Department
Program
Project Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
355937
Name
Gunning Patrick T
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Extending life in refractory medulloblastoma patients with cancer stem cell killing small molecules
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$753,524
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Drug Discovery; Medicinal Chemistry; Molecular Therapeutics; Protein-Protein Interactions; Recurrent Medulloblastoma
Abstract
We have discovered a small drug-like molecule that has demonstrated extremely potent killing of chemotherapy and radiation-resistant children's brain cancer cells. Children that develop this resistant form of brain cancer are palliative with no other available treatment options. This molecule, named JP-4-94, was discovered by rationale design, and found to exhibit exquisite potency against a protein, c-Myc, long known to be a major driver of many human cancers. Moreover, this molecule has been validated in mouse models as having incredible metabolic stability and can be found in high concentrations in the blood stream with no toxicity to the mouse. We propose to optimize this compound further toward a preclinical candidate and evaluate its efficacy in the most aggressive of Children's brain cancer. We expect by grant end, that we will have identified an advanced preclinical candidate.
Competitiondate
201610
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Gunning, Patrick T
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $753,524~ $0~
